Literature DB >> 27744356

Dysregulated interleukin-23 signalling contributes to the increased collagen production in scleroderma fibroblasts via balancing microRNA expression.

Wakana Nakayama1, Masatoshi Jinnin2, Yukiko Tomizawa1, Kayo Nakamura1, Hideo Kudo1, Kuniko Inoue1, Katsunari Makino1, Noritoshi Honda1, Ikko Kajihara1, Satoshi Fukushima1, Hironobu Ihn1.   

Abstract

OBJECTIVES: The overexpression of IL-12 family cytokines is implicated in the pathogenesis of SSc, but their exact role is still unclear. The aim of this study was to investigate the regulation of extracellular matrix expression by IL-23 and its contribution to the phenotype of SSc.
METHODS: The mRNA expression was determined by PCR array and real-time PCR. The expression levels of proteins were determined by immunoblotting and immunohistochemical staining. The effect of IL-23 on dermal fibrosis in vivo was examined in a mouse model of SSc induced by bleomycin injection.
RESULTS: Among the IL-12 family members, IL-23 decreased expression of type I collagen protein in cultured normal dermal fibroblasts. We found that miR-4458 and miR-18a mediated the reduction of collagen expression by IL-23. On the contrary, IL-23 up-regulated type I collagen expression in SSc fibroblasts. The paradoxical effects of IL-23 in SSc fibroblasts were also mediated by the balance between miR-4458 and miR-18a expression. Moreover, we revealed that injection of IL-23 into the mouse skin accelerated skin fibrosis.
CONCLUSION: This is the first study to report that the balance of two miRNAs is involved in the collagen dysregulation in SSc fibroblasts. Clarification of the regulatory mechanism of tissue fibrosis by IL-23 in SSc skin may lead to a better understanding of this disease and new therapeutic approaches.
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  collagen; cytokine; fibrosis; microRNA; scleroderma

Mesh:

Substances:

Year:  2016        PMID: 27744356     DOI: 10.1093/rheumatology/kew336

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  4 in total

1.  Aberrant expression of interleukin-23-regulated miRNAs in T cells from patients with ankylosing spondylitis.

Authors:  Ning-Sheng Lai; Hui-Chun Yu; Chien-Hsueh Tung; Kuang-Yung Huang; Hsien-Bin Huang; Ming-Chi Lu
Journal:  Arthritis Res Ther       Date:  2018-11-21       Impact factor: 5.156

Review 2.  The function of ncRNAs in rheumatic diseases.

Authors:  Weilin Chen; Di Liu; Quan-Zhen Li; Honglin Zhu
Journal:  Epigenomics       Date:  2019-06-07       Impact factor: 4.778

Review 3.  Jak Inhibitors for Treatment of Autoimmune Diseases: Lessons from Systemic Sclerosis and Systemic Lupus Erythematosus.

Authors:  Przemysław Kotyla; Olga Gumkowska-Sroka; Bartosz Wnuk; Kacper Kotyla
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-28

Review 4.  Natural Formulations: Novel Viewpoint for Scleroderma Adjunct Treatment.

Authors:  Shirin Assar; Hosna Khazaei; Maryam Naseri; Fardous El-Senduny; Saeideh Momtaz; Mohammad Hosein Farzaei; Javier Echeverría
Journal:  J Immunol Res       Date:  2021-06-24       Impact factor: 4.818

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.